title: Comment on "SUMO deconjugation is required for arsenic-triggered ubiquitylation of PML".
abstract: Fasci et al proposed that a SENP1-mediated switch from SUMO2 to SUMO1 conjugation on Lys(65) in promyelocytic leukemia protein (PML) is required for arsenic-induced PML degradation, the basis for the antileukemic activity of arsenic. We found that PML or PML/RARA (retinoic acid receptor α) mutants that cannot be SUMO-conjugated on this specific site nevertheless underwent immediate arsenic-triggered SUMO modification. Moreover, these mutants were efficiently degraded in cells and even in vivo, demonstrating that SUMOylation of Lys(65) was dispensable for arsenic response. The existence and putative role of a SUMO switch on PML should thus be reassessed.
authors: Université Paris Diderot, Sorbonne Paris Cité, Institut Universitaire d'Hématologie, Hôpital Saint Louis, Paris 75010, France. INSERM UMR 944, Equipe Labellisée par la Ligue Nationale contre le Cancer, Hôpital Saint Louis, Paris 75010, France. CNRS UMR 7212, Hôpital Saint Louis, Paris 75010, France.
authors: Omar
authors: O
authors: Ferhi
authors: Université Paris Diderot, Sorbonne Paris Cité, Institut Universitaire d'Hématologie, Hôpital Saint Louis, Paris 75010, France. INSERM UMR 944, Equipe Labellisée par la Ligue Nationale contre le Cancer, Hôpital Saint Louis, Paris 75010, France. CNRS UMR 7212, Hôpital Saint Louis, Paris 75010, France.
authors: Laurent
authors: L
authors: Pérès
authors: Université Paris Diderot, Sorbonne Paris Cité, Institut Universitaire d'Hématologie, Hôpital Saint Louis, Paris 75010, France. INSERM UMR 944, Equipe Labellisée par la Ligue Nationale contre le Cancer, Hôpital Saint Louis, Paris 75010, France. CNRS UMR 7212, Hôpital Saint Louis, Paris 75010, France.
authors: Sarah
authors: S
authors: Tessier
authors: Université Paris Diderot, Sorbonne Paris Cité, Institut Universitaire d'Hématologie, Hôpital Saint Louis, Paris 75010, France. INSERM UMR 944, Equipe Labellisée par la Ligue Nationale contre le Cancer, Hôpital Saint Louis, Paris 75010, France. CNRS UMR 7212, Hôpital Saint Louis, Paris 75010, France. Assistance Publique des Hôpitaux de Paris, Oncologie Moléculaire, Hôpital Saint Louis, Paris 75010, France. Collège de France, PSL (Paris Sciences et Lettres) University, Paris, 75231 Paris Cedex 05, France. hugues.dethe@inserm.fr valerie.lallemand@inserm.fr.
authors: Hugues
authors: H
authors: de Thé
authors: Université Paris Diderot, Sorbonne Paris Cité, Institut Universitaire d'Hématologie, Hôpital Saint Louis, Paris 75010, France. INSERM UMR 944, Equipe Labellisée par la Ligue Nationale contre le Cancer, Hôpital Saint Louis, Paris 75010, France. CNRS UMR 7212, Hôpital Saint Louis, Paris 75010, France. hugues.dethe@inserm.fr valerie.lallemand@inserm.fr.
authors: Valérie
authors: V
authors: Lallemand-Breitenbach
mesh_terms: D001151:Arsenic; D009687:Nuclear Proteins / Q000235:genetics; D000071156:Promyelocytic Leukemia Protein; D025521:Tumor Suppressor Proteins / Q000235:genetics; D054875:Ubiquitination
chemical_list: D009687:Nuclear Proteins; D000071156:Promyelocytic Leukemia Protein; D025521:Tumor Suppressor Proteins; D001151:Arsenic